Paratek Pharmaceuticals (Paratek Pharmaceuticals) Cash-to-Debt : 0.16 (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Paratek Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.16.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Paratek Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Paratek Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

PRTK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 1.23 Max: No Debt
Current: 0.16

During the past 13 years, Paratek Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.13. And the median was 1.23.

PRTK's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.52 vs PRTK: 0.16

Paratek Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Paratek Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Paratek Pharmaceuticals Cash-to-Debt Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

1.09

0.82

0.50

0.37

0.13

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															0.27	0.22	0.13	0.17	0.16

Competitive Comparison of Paratek Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Paratek Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Cash-to-Debt falls into.

Paratek Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Paratek Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	34.248	/	(0	+	258.414)
	=	0.13

Paratek Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	42.685	/	(164.042	+	95.714)
	=	0.16

Paratek Pharmaceuticals (NAS:PRTK) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Paratek Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Executives

Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh	director, officer: CEO	75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel	officer: CLO, General Counsel & Sec.	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow	officer: President & Chief Commercial	C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner	officer: Chief Development & Regulatory	C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann	director	LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham	director, officer: Exec. Chairman of the Board	890 WINTER STREET, WALTHAM MA 02451
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan	officer: Chief Financial Officer	75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199